NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

PYXS

Pyxis Oncology Inc

Jul 11 • 04:00PM ET

1.16

Dollar change -0.03
Percentage change -2.52	%

Healthcare • Biotechnology • USA • NASD

Peers: FATE EXEL ADAP MRSN IMTX MGNX SRRK IMAB AFMD

| Held by: VTI VXF IBB VTWO IWC VTWV MSSM IBBQ BIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.58	Insider Own	28.94%	Shs Outstand	61.63M	Perf Week	5.45%
Market Cap	71.86M	Forward P/E	-	EPS next Y	-1.20	Insider Trans	0.00%	Shs Float	44.02M	Perf Month	-13.43%
Enterprise Value	-15.20M	PEG	-	EPS next Q	-0.35	Inst Own	39.14%	Short Float	11.51%	Perf Quarter	17.72%
Income	-95.23M	P/S	-	EPS this Y	-4.29%	Inst Trans	3.72%	Short Ratio	9.12	Perf Half Y	-33.33%
Sales	0.00M	P/B	0.69	EPS next Y	13.20%	ROA	-53.49%	Short Interest	5.06M	Perf YTD	-25.64%
Book/sh	1.67	P/C	0.67	EPS next 5Y	2.24%	ROE	-66.30%	52W High	5.39 -78.48%	Perf Year	-59.01%
Cash/sh	1.73	P/FCF	-	EPS past 3/5Y	17.52% -74.92%	ROIC	-78.42%	52W Low	0.83 39.22%	Perf 3Y	-52.65%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.88% 6.79%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-14.09%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.75	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	48.53	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	7.75	EPS Q/Q	-445.83%	SMA20	-1.07%	Beta	1.13	Target Price	6.20
Payout	-	Debt/Eq	0.19	Sales Q/Q	-100.00%	SMA50	-2.41%	Rel Volume	1.29	Prev Close	1.19
Employees	44	LT Debt/Eq	0.18	Earnings	May 15 BMO	SMA200	-36.50%	Avg Volume	555.61K	Price	1.16
IPO	Oct 08, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-19.05% -	Trades		Volume	715,046	Change	-2.52%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-21-24	Downgrade	William Blair	Outperform → Mkt Perform
Nov-08-24	Initiated	Stephens	Overweight	$13
Aug-08-24	Initiated	Stifel	Buy	$10
May-07-24	Resumed	Jefferies	Buy	$10
Feb-09-24	Initiated	BTIG Research	Buy	$8
Jan-23-24	Initiated	Leerink Partners	Outperform	$12
Sep-05-23	Initiated	RBC Capital Mkts	Outperform	$7
Nov-02-21	Initiated	Jefferies	Buy	$25
Nov-02-21	Initiated	Credit Suisse	Outperform	$19
Nov-02-21	Initiated	BofA Securities	Neutral	$16

Jun-30-25 04:30PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-15-25 07:00AM	Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-14-25 07:30AM	Pyxis Oncology to Participate in Two Upcoming Investor Conferences (GlobeNewswire) -10.08%
Apr-25-25 01:17PM	Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC (GlobeNewswire)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks)
09:32AM	Loading…
Apr-23-25 09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks) +5.88%
Apr-16-25 09:45AM	Top Cancer Stocks to Buy to Boost Your Portfolio's Health (Zacks)
Apr-02-25 07:30AM	Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum (GlobeNewswire) +11.48%
Mar-25-25 04:30PM	Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025 (GlobeNewswire) -8.70%
Mar-18-25 07:30AM	Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -8.62%
Mar-03-25 07:30AM	Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference (GlobeNewswire) -6.72%
Feb-26-25 07:30AM	Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer (GlobeNewswire) -5.83%
Feb-04-25 07:30AM	Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial (GlobeNewswire)
Dec-21-24 07:40AM	Pyxis Oncology price target lowered to $8 from $10 at RBC Capital (TipRanks)
Dec-19-24 04:08PM	Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 (GlobeNewswire) +9.74%
04:05PM	Loading…
Nov-20-24 04:05PM	Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data (GlobeNewswire) -8.17% -45.03%
Nov-12-24 07:30AM	Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024 (GlobeNewswire)
Nov-11-24 07:00AM	Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201 (GlobeNewswire) +7.24%
Aug-29-24 07:30AM	Pyxis Oncology to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 04:05PM	Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024 (GlobeNewswire)
Jul-29-24 08:00AM	Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jun-28-24 04:30PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-10-24 07:30AM	Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger (GlobeNewswire)
May-30-24 07:30AM	Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 03:53PM	PYXS Stock Earnings: Pyxis Oncology Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:40AM	Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024 (GlobeNewswire)
May-09-24 07:30AM	Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +5.62%
Apr-12-24 09:55AM	Does Pyxis Oncology (PYXS) Have the Potential to Rally 61.29% as Wall Street Analysts Expect? (Zacks) -6.64%
Mar-28-24 04:30PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +12.44%
07:30AM	Loading…
Mar-27-24 07:30AM	Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights (GlobeNewswire) +9.66%
Mar-26-24 12:00PM	All You Need to Know About Pyxis Oncology (PYXS) Rating Upgrade to Buy (Zacks)
Mar-21-24 01:53PM	PYXS Stock Earnings: Pyxis Oncology Beats EPS for Q4 2023 (InvestorPlace) -8.66%
09:11AM	Pyxis Oncology Inc (PYXS) Reports Encouraging Clinical Progress Amid Financial Challenges (GuruFocus.com)
07:30AM	Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023 (GlobeNewswire)
Mar-13-24 08:00AM	Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA (GlobeNewswire) -6.14%
Mar-07-24 04:30PM	Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024 (GlobeNewswire) -9.63%
Mar-05-24 04:45PM	Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting (GlobeNewswire)
Feb-27-24 08:00AM	Pyxis Oncology Announces $50 Million Private Placement (GlobeNewswire) +33.26%
Dec-29-23 04:30PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +14.44%
Nov-28-23 07:00AM	Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer (GlobeNewswire)
Nov-07-23 04:30PM	Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update (GlobeNewswire)
Oct-23-23 11:27AM	Inspiring the Next Generation of Entrepreneurs at the Diversity and Equity Accelerator through Learning for Startups (DEALS) Workshop (PR Newswire)
Oct-13-23 09:00AM	New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review (PR Newswire)
Sep-27-23 09:18AM	Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023 (GlobeNewswire)
Sep-14-23 05:03PM	Insider Sell: President and CEO Lara Sullivan Sells 27,917 Shares of Pyxis Oncology Inc (GuruFocus.com)
Aug-31-23 04:01PM	Pyxis Oncology to Participate in Two Upcoming Investment Conferences (GlobeNewswire) +6.42%
Aug-23-23 08:35AM	Pyxis Oncology Successfully Completes Acquisition of Apexigen (GlobeNewswire)
Aug-11-23 07:00AM	Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update (GlobeNewswire) +6.61%
Aug-01-23 04:01PM	Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jun-30-23 05:00PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-23 08:30AM	Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs (GlobeNewswire)
May-24-23 06:45AM	Pyxis Oncology to Acquire Apexigen (GlobeNewswire) -10.46%
May-11-23 07:00AM	Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update (GlobeNewswire)
Mar-31-23 05:00PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -33.17%
Mar-30-23 02:16PM	Pyxis Stock Is Up 170% This Week. How Much Higher Can It Go? (TipRanks) +32.16%
Mar-22-23 06:45AM	Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update (GlobeNewswire)
Mar-16-23 07:30AM	Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors (GlobeNewswire) +7.46%
Feb-13-23 08:00AM	Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference (GlobeNewswire)
Dec-23-22 04:45PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.79%
Dec-01-22 06:45AM	Pyxis Oncology Announces FDA Clearance of Two IND Applications (GlobeNewswire)
Nov-01-22 06:30AM	Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update (GlobeNewswire) -9.63%
Sep-30-22 05:00PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-15-22 07:00AM	Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update (GlobeNewswire)
Jul-12-22 06:45AM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-28-22 06:35AM	Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference (GlobeNewswire)
Jun-21-22 10:40AM	Great news for Pyxis Oncology, Inc. (NASDAQ:PYXS): Insiders acquired stock in large numbers last year (Simply Wall St.)
May-19-22 06:35AM	Pyxis Oncology Announces Presentations at Upcoming Investor Conferences (GlobeNewswire)
May-13-22 08:03AM	Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update (GlobeNewswire) -9.01%
May-07-22 10:34AM	Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely? (Simply Wall St.)
Apr-27-22 06:35AM	Pyxis Oncology to Participate in Fireside Chat at BofA Securities 2022 Healthcare Conference (GlobeNewswire)
Apr-13-22 06:35AM	Pyxis Oncology Announces Leadership Changes (GlobeNewswire)
Apr-08-22 01:05PM	Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-29-22 11:00AM	Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology (PR Newswire)
06:35AM	Pyxis Oncology Provides Corporate and Financial Update (GlobeNewswire)
Mar-22-22 06:35AM	Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022 (GlobeNewswire) -8.04%
Jan-10-22 11:17AM	Quite a few insiders invested in Pyxis Oncology, Inc. (NASDAQ:PYXS) last year which is positive news for shareholders (Simply Wall St.)
Dec-15-21 08:00AM	Pyxis to be Added to Russell 2000® Index (GlobeNewswire)
Dec-09-21 08:30AM	Pyxis Oncology Appoints Martina Molsbergen as Interim Chief Business Officer (GlobeNewswire)
Nov-15-21 07:15AM	Pyxis Reports Financial Results for the Third Quarter of 2021 and Provides Business Update (GlobeNewswire)
Nov-10-21 08:00AM	Pyxis Oncology to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-08-21 03:31PM	Pyxis Oncology well positioned to advance its work against cancer amid public debut: CEO (Yahoo Finance Video)
Oct-07-21 10:24PM	Pyxis Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HUMPHREY RACHEL	Director	Apr 21 '25	Proposed Sale	1.03	13,896	14,362		Apr 21 04:14 PM
HUMPHREY RACHEL	Director	Apr 17 '25	Proposed Sale	0.97	200	194		Apr 17 04:27 PM
HUMPHREY RACHEL	Director	Apr 14 '25	Proposed Sale	0.97	1,400	1,362		Apr 14 04:05 PM
Connealy Pamela Ann	CFO & COO	Nov 26 '24	Buy	1.96	88,850	174,364	1,199,143	Nov 27 05:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PYXS

Pyxis Oncology Inc

Upgrade your FINVIZ experience